Trial Profile
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Lesinidase alfa (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions; First in man
- Sponsors Alexion Pharmaceuticals; Synageva BioPharma
- 01 Jul 2019 This trial has been Discontinued in UK - MHRA, according to European Clinical Trials Database.
- 12 Jun 2018 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 The study has been suspended in Spain.